To view this email as a web page, click here.
 
CLINICAL UPDATES
 
Untreated MIBC has short natural course, significant morbidity
“There appears to be a strikingly high likelihood of increased morbidity and poor outcomes in patient who are not receiving definitive therapy,” writes Badar M. Mian, MD.
Read his column
 
Germline variants found in 18% of patients with familial UC
About one in five patients with familial urothelial carcinoma have pathogenic germline variants, according to an analysis of 79 such patients using germline multigene panel testing.
Learn more
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
MORE FROM UROLOGY TIMES
 
PCa study evaluates ‘clinically meaningful’ margins, recurrence
DDR mutations linked to improved urothelial cancer outcomes
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.